DiaMedica Therapeutics (NASDAQ:DMAC) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a sell rating to a hold rating in a report issued on Monday.

Several other analysts also recently commented on the stock. Lake Street Capital increased their price objective on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, July 18th. Craig Hallum increased their price objective on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, July 18th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, August 15th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, DiaMedica Therapeutics currently has an average rating of “Buy” and an average price target of $12.33.

DiaMedica Therapeutics Price Performance

Shares of DiaMedica Therapeutics stock opened at $6.00 on Monday. DiaMedica Therapeutics has a 1 year low of $3.19 and a 1 year high of $6.82. The company has a 50-day moving average of $4.48 and a 200 day moving average of $4.56. The firm has a market cap of $310.14 million, a price-to-earnings ratio of -8.70 and a beta of 1.25.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). On average, equities analysts anticipate that DiaMedica Therapeutics will post -0.59 EPS for the current year.

Insider Activity

In related news, major shareholder Jan Stahlberg purchased 1,542,857 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were purchased at an average price of $3.50 per share, with a total value of $5,399,999.50. Following the acquisition, the insider directly owned 6,764,465 shares in the company, valued at $23,675,627.50. The trade was a 29.55% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.30% of the stock is currently owned by insiders.

Institutional Trading of DiaMedica Therapeutics

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its holdings in shares of DiaMedica Therapeutics by 24.4% in the second quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock worth $74,000 after buying an additional 3,709 shares during the last quarter. Bank of America Corp DE lifted its holdings in DiaMedica Therapeutics by 3,710.3% during the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after purchasing an additional 8,274 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in DiaMedica Therapeutics during the second quarter valued at approximately $56,000. Marshall Wace LLP lifted its holdings in DiaMedica Therapeutics by 227.8% during the second quarter. Marshall Wace LLP now owns 61,719 shares of the company’s stock valued at $241,000 after purchasing an additional 42,890 shares in the last quarter. Finally, Invesco Ltd. purchased a new position in DiaMedica Therapeutics during the second quarter valued at approximately $54,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.